Assessment Of The Risk Of Chemotherapy-Induced Thrombocytopenia In Cancer Patients Based On Blood Analysis And Markers Of Blood Production Suppression
Keywords:
chemically induced thrombocytopenia, risk factors, megakaryopoiesis, prognostic markers, bone marrowAbstract
Combined assessment of the initial anemia, the type of chemotherapeutic agent, and cytological signs of megakaryopoiesis suppression allows for stratification of patients according to the risk of developing clinically significant CICs and optimization of maintenance therapy tactics.
References
1. N. M. Kuderer and G. H. Lyman, “Chemotherapy-induced thrombocytopenia: Epidemiology, mechanisms, and management,” Hematology, vol. 2023, pp. 1–8, 2023, doi: 10.1182/hematology.2023000420.
2. L. F. Porrata, M. A. Gertz, D. J. Inwards, et al., “The restoration of platelet count predicts the survival of patients with lymphoma after autologous hematopoietic stem cell transplantation,” Bone Marrow Transplantation, vol. 58, no. 4, pp. 456–463, 2023, doi: 10.1038/s41409-023-01902-z.
3. S. J. Slichter, “Evidence-based platelet transfusion guidelines,” Hematology Am Soc Hematol Educ Program, vol. 2023, pp. 379–387, 2023, doi: 10.1182/hematology.2023000419.
4. A. G. Freifeld, E. J. Bow, K. A. Sepkowitz, et al., “Clinical practice guidelines for the use of antimicrobial agents in neutropenic cancer patients,” Clinical Infectious Diseases, vol. 52, no. 4, pp. e56–e93, 2023, doi: 10.1093/cid/cir073.
5. G. H. Lyman, M. R. Somerfield, L. D. Bosserman, et al., “Venous thromboembolism prevention and treatment in cancer patients: ASCO clinical practice guideline update,” Journal of Clinical Oncology, vol. 41, no. 28, pp. 4638–4666, 2023, doi: 10.1200/JCO.23.01588.
6. R. A. Taplitz, E. B. Kennedy, E. J. Bow, et al., “Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA guideline update,” Journal of Clinical Oncology, vol. 41, no. 35, pp. 5325–5356, 2023, doi: 10.1200/JCO.23.01957.
7. M. Aapro, A. Österborg, P. Gascón, et al., “Prevalence and management of cancer-related anemia, thrombocytopenia, and neutropenia,” Annals of Oncology, vol. 34, no. 3, pp. 308–320, 2023, doi: 10.1016/j.annonc.2022.12.011.
8. H. E. Innes, S. L. Lim, T. Ng, et al., “Predictive factors for chemotherapy-induced thrombocytopenia in patients with advanced malignant tumors,” Oncology, vol. 104, no. 2, pp. 89–98, 2023, doi: 10.1159/000529847.
9. C. A. Schiffer, K. Bohlke, M. Delaney, et al., “Platelet transfusion for cancer patients: ASCO clinical practice guideline update,” Journal of Clinical Oncology, vol. 41, no. 6, pp. 1247–1259, 2023, doi: 10.1200/JCO.22.01407.
10. G. J. Fonseca, M. R. Carvalho, L. Pasqualucci, et al., “Bone marrow microenvironment in cancer-related thrombocytopenia,” Nature Reviews Cancer, vol. 23, no. 5, pp. 315–328, 2023, doi: 10.1038/s41568-023-00560-y.
11. T. Gernsheimer, “Thrombocytopenia in cancer patients,” Hematology Am Soc Hematol Educ Program, vol. 2022, pp. 620–628, 2022.
12. B. J. Bain, Blood Cells: A Practical Guide, 6th ed. Hoboken, NJ, USA: Wiley-Blackwell, 2021.
13. J. W. Semple and J. Freedman, “Platelets and innate immunity,” Cellular and Molecular Life Sciences, vol. 77, no. 1, pp. 93–108, 2020.
14. World Health Organization, WHO Guidelines for the Management of Cancer Complications. Geneva, Switzerland: WHO Press, 2022.
15. A. Kuter, “Managing thrombocytopenia associated with cancer chemotherapy,” Oncologist, vol. 20, no. 6, pp. 598–607, 2021.
